ARTICLE | Clinical News
GFT505: Phase II started
September 27, 2010 7:00 AM UTC
Genfit began the 12-week, double-blind, placebo-controlled, European Phase II GFT505-210-5 trial to evaluate 80 mg/day oral GFT505 in 120 newly-diagnosed Type II diabetics. ...